Use of Angiotensin Converting Enzyme Inhibitors is Associated with Reduced Risk of Late Bladder Toxicity Following Radiotherapy for Prostate Cancer

Background And Purpose: Genome-wide association studies (GWAS) of late hematuria following prostate cancer radiotherapy identified single nucleotide polymorphisms (SNPs) near AGT, encoding angiotensinogen. We tested the hypothesis that patients taking angiotensin converting enzyme inhibitors (ACEi) have a reduced risk of late hematuria. We additionally tested genetically-defined hypertension.

Materials And Methods: Prostate cancer patients undergoing potentially-curative radiotherapy were enrolled onto two multi-center observational studies, URWCI (N = 256) and REQUITE (N = 1,437). Patients were assessed pre-radiotherapy and followed prospectively for development of toxicity for up to four years. The cumulative probability of hematuria was estimated by the Kaplan-Meier method. Multivariable grouped relative risk models assessed the effect of ACEi on time to hematuria adjusting for clinical factors and stratified by enrollment site. A polygenic risk score (PRS) for blood pressure was tested for association with hematuria in REQUITE and our Radiogenomics Consortium GWAS.

Results: Patients taking ACEi during radiotherapy had a reduced risk of hematuria (HR 0.51, 95%CI 0.28 to 0.94, p = 0.030) after adjusting for prior transurethral prostate and/or bladder resection, heart disease, pelvic node radiotherapy, and bladder volume receiving 70 Gy, which are associated with hematuria. A blood pressure PRS was associated with hypertension (odds ratio per standard deviation 1.38, 95%CI 1.31 to 1.46, n = 5,288, p < 0.001) but not hematuria (HR per standard deviation 0.96, 95%CI 0.87 to 1.06, n = 5,126, p = 0.41).

Conclusions: Our study is the first to show a radioprotective effect of ACEi on bladder in an international, multi-site study of patients receiving pelvic radiotherapy. Mechanistic studies are needed to understand how targeting the angiotensin pathway protects the bladder.

Citing Articles

The Effect of the Concurrent Use of Angiotensin-Converting Enzyme Inhibitors or Receptor Blockers on Toxicity and Outcomes in Patients Treated with Radiotherapy: A Systematic Review and Meta-Analysis.

Liao W, Shokr H, Faivre-Finn C, Dempsey C, Williams K, Chen L Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861167 PMC: 11769270. DOI: 10.3390/ph18010105.

Radiation-induced multi-organ injury.

Molinar-Inglis O, DiCarlo A, Lapinskas P, Rios C, Satyamitra M, Silverman T Int J Radiat Biol. 2024; 100(3):486-504.

PMID: 38166195 PMC: 11874064. DOI: 10.1080/09553002.2023.2295298.

Clinical impact of radiation-induced myocardial damage detected by cardiac magnetic resonance imaging and dose-volume histogram parameters of the left ventricle as prognostic factors of cardiac events after chemoradiotherapy for esophageal cancer.

Umezawa R, Ota H, Takagi H, Kadoya N, Nakajima Y, Takahashi N J Radiat Res. 2023; 64(4):702-710.

PMID: 37308130 PMC: 10354843. DOI: 10.1093/jrr/rrad040.

Biological sex differences in renin angiotensin system enzymes ACE and ACE2 regulate normal tissue response to radiation injury.

Sharma G, Frei A, Fish B, Gasperetti T, Veley D, Szalewski N Front Physiol. 2023; 14:1191237.

PMID: 37275232 PMC: 10235526. DOI: 10.3389/fphys.2023.1191237.

Predicting the germline dependence of hematuria risk in prostate cancer radiotherapy patients.

Oh J, Lee S, Thor M, Rosenstein B, Tannenbaum A, Kerns S Radiother Oncol. 2023; 185:109723.

PMID: 37244355 PMC: 10524941. DOI: 10.1016/j.radonc.2023.109723.

References

Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2008; 42(2):377-81. PMC: 2700030. DOI: 10.1016/j.jbi.2008.08.010. View

Liu M, Pickles T, Agranovich A, Berthelet E, Duncan G, Keyes M . Impact of neoadjuvant androgen ablation and other factors on late toxicity after external beam prostate radiotherapy. Int J Radiat Oncol Biol Phys. 2003; 58(1):59-67. DOI: 10.1016/s0360-3016(03)00777-6. View

Wedlake L, Silia F, Benton B, Lalji A, Thomas K, Dearnaley D . Evaluating the efficacy of statins and ACE-inhibitors in reducing gastrointestinal toxicity in patients receiving radiotherapy for pelvic malignancies. Eur J Cancer. 2012; 48(14):2117-24. DOI: 10.1016/j.ejca.2011.12.034. View

Barnett G, Thompson D, Fachal L, Kerns S, Talbot C, Elliott R . A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity. Radiother Oncol. 2014; 111(2):178-85. DOI: 10.1016/j.radonc.2014.02.012. View

Werner E, Broxson E, TUCKER E, Giroux D, Shults J, Abshire T . Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr. 1993; 123(6):893-8. DOI: 10.1016/s0022-3476(05)80384-1. View

Vavassori V, Fiorino C, Rancati T, Magli A, Fellin G, Baccolini M . Predictors for rectal and intestinal acute toxicities during prostate cancer high-dose 3D-CRT: results of a prospective multicenter study. Int J Radiat Oncol Biol Phys. 2007; 67(5):1401-10. DOI: 10.1016/j.ijrobp.2006.10.040. View

Choe K, Jani A, Liauw S . External beam radiotherapy for prostate cancer patients on anticoagulation therapy: how significant is the bleeding toxicity?. Int J Radiat Oncol Biol Phys. 2009; 76(3):755-60. DOI: 10.1016/j.ijrobp.2009.02.026. View

Harris P, Taylor R, Minor B, Elliott V, Fernandez M, ONeal L . The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019; 95:103208. PMC: 7254481. DOI: 10.1016/j.jbi.2019.103208. View

Barnett G, De Meerleer G, Gulliford S, Sydes M, Elliott R, Dearnaley D . The impact of clinical factors on the development of late radiation toxicity: results from the Medical Research Council RT01 trial (ISRCTN47772397). Clin Oncol (R Coll Radiol). 2011; 23(9):613-24. DOI: 10.1016/j.clon.2011.03.001. View

10.

Schaake W, van der Schaaf A, van Dijk L, van den Bergh A, Langendijk J . Development of a prediction model for late urinary incontinence, hematuria, pain and voiding frequency among irradiated prostate cancer patients. PLoS One. 2018; 13(7):e0197757. PMC: 6049922. DOI: 10.1371/journal.pone.0197757. View

11.

Alashkham A, Paterson C, Rauchhaus P, Nabi G . Can Angiotensin-Converting Enzyme Inhibitors Reduce the Incidence, Severity, and Duration of Radiation Proctitis?. Int J Radiat Oncol Biol Phys. 2015; 94(1):93-101. DOI: 10.1016/j.ijrobp.2015.09.013. View

12.

Seibold P, Webb A, Aguado-Barrera M, Azria D, Bourgier C, Brengues M . REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer. Radiother Oncol. 2019; 138:59-67. DOI: 10.1016/j.radonc.2019.04.034. View

13.

Devisetty K, Zorn K, Katz M, Jani A, Liauw S . External beam radiation therapy after transurethral resection of the prostate: a report on acute and late genitourinary toxicity. Int J Radiat Oncol Biol Phys. 2010; 77(4):1060-5. DOI: 10.1016/j.ijrobp.2009.06.078. View

14.

Davey Smith G, Ebrahim S . 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease?. Int J Epidemiol. 2003; 32(1):1-22. DOI: 10.1093/ije/dyg070. View

15.

Smit S, Heyns C . Management of radiation cystitis. Nat Rev Urol. 2010; 7(4):206-14. DOI: 10.1038/nrurol.2010.23. View

16.

Cohen E, Moulder J, Fish B, Hill P . Prophylaxis of experimental bone marrow transplant nephropathy. J Lab Clin Med. 1994; 124(3):371-80. View

17.

Fachal L, Gomez-Caamano A, Barnett G, Peleteiro P, Carballo A, Calvo-Crespo P . A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1. Nat Genet. 2014; 46(8):891-4. DOI: 10.1038/ng.3020. View

18.

Martin S, Begun E, Samir E, Azaiza M, Allegro S, Abdelhady M . Incidence and Morbidity of Radiation-Induced Hemorrhagic Cystitis in Prostate Cancer. Urology. 2019; 131:190-195. DOI: 10.1016/j.urology.2019.05.034. View

19.

Peeters S, Heemsbergen W, van Putten W, Slot A, Tabak H, Mens J . Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys. 2005; 61(4):1019-34. DOI: 10.1016/j.ijrobp.2004.07.715. View

20.

Fiorino C, Cozzarini C, Rancati T, Briganti A, Cattaneo G, Mangili P . Modelling the impact of fractionation on late urinary toxicity after postprostatectomy radiation therapy. Int J Radiat Oncol Biol Phys. 2014; 90(5):1250-7. DOI: 10.1016/j.ijrobp.2014.08.347. View